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The ABO blood group system is the most clinically significant 
system in transfusion medicine. Although serologic typing for 
ABO antigens is routine and reliable, molecular methods can be 
used to predict an ABO type in the absence of a blood specimen 
as well as to investigate ABO typing discrepancies often caused 
by ABO subgroups that cause weakened antigen expression, weak 
or missing serum reactivity, and/or extra red blood cell reactivity. 
By detecting single nucleotide variants that are hallmarks of 
the major ABO alleles, low-resolution genotyping methods can 
be used to make allele assignments and predict phenotypes. 
This approach has become a dependable tool, initially to resolve 
typing discrepancies identified in blood banks and donor centers 
and, more recently, to predict the ABO group in bone marrow 
transplant donors and in deceased donors of solid organs. The 
aim of this report is to compare two different low-resolution 
polymerase chain reaction (PCR)-based methods: a PCR-
restriction fragment length polymorphism (RFLP) implemented 
based on a publication and a commercially available TaqMan-
based sequence-specific primer-PCR for resolution of ABO 
typing discrepancies. Fifty-six peripheral blood samples from 31 
patients and 25 blood donors were used to isolate genomic DNA 
and perform genotyping. Results of 49 of the 56 samples (87.5%) 
were concordant between methods, three samples yielded an 
unexpected banding pattern on the PCR-RFLP method, and four 
sample results were discordant between assays. The discordances 
all involved group A versus A2 discrepancies. Sanger sequencing 
was used as a high-resolution genotyping method to resolve 
discrepancies between the two low-resolution methods. This 
study demonstrates that, in the majority of cases, a low-resolution 
genotyping method can resolve an ABO discrepancy. Although 
there is no U.S. Food and Drug Administration–approved 
genotyping method for ABO determination, molecular testing 
for investigation of discrepancies is a useful tool for blood banks 
and transplant programs. Immunohematology 2019;35: 
149–153.
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The ABO blood group system was discovered in 1900; the 
current nomenclature was established in 1927 by Landsteiner.1 
The system comprises four main phenotype groups: A, B, 
AB, and O. These groups arise from the activity of one or 
two distinct glycosyltransferases: A glycosyltransferase and 
B glycosyltransferase. These enzymes catalyze the transfer 
of the terminal sugar residues (N-acetyl-galactosamine or 
d-galactose) to the H-active chain on red blood cell (RBC) 
membrane glycoproteins and glycolipids—producing A 
antigens and/or B antigens, respectively. The lack of activity of 
either of these enzymes results in the group O phenotype, and 
the activity of both glycosyltransferases results in the group 
AB phenotype.  
The ABO gene contains seven exons and spans over 20 
kilobases (kb) on chromosome 9 (9q34). The reference allele is 
denoted as ABO*A1.01, which encodes A glycosyltransferase, 
which is responsible for the A antigen. The common group O 
phenotype is defined by a single nucleotide deletion at c.261, 
causing a frameshift mutation resulting in a premature stop 
codon of the amino acid sequence and a subsequent null 
phenotype of the enzyme. Genetic variation within the ABO 
gene that changes the specificity or activity of the enzyme can 
result in an altered ABO phenotype. Many ABO subgroups 
have been classified and categorized within each phenotypic 
group. To date, more than 200 variant alleles have been 
identified in the ABO blood group system.2
ABO discrepancies have many causes, including 
recent transfusion of blood products, technical error, ABO-
incompatible hematopoietic stem cell transplant, age, and 
medical condition.3 Samples can demonstrate a RBC or 
plasma discrepancy, with weak, missing, or extra reactivity. 
Standard serologic methods can be adjusted to resolve such 
discrepancies, including changing incubation temperature or 
time and using lectins to differentiate reactivity for A1 versus 
non-A1.4
Patient and donor samples referred to the National 
Molecular Laboratory for ABO genotyping for investigation 
of serologic discrepancies in 2017 and 2018 were included in 
this study. In some cases, little or no serologic information was 
provided. For this report, we compared the results obtained 
from two genotyping methods when used to test samples 
submitted for investigation of typing discrepancies. Testing 
Comparison of ABO genotyping methods: a 
study of two low-resolution polymerase chain 
reaction assays in a clinical testing laboratory
J.A. Keller, T. Horn, S. Scholz, S. Koenig, and M.A. Keller
oriGinal report
150 IMMUNOHEMATOLOGY, Volume 35, Number 4, 2019
J.A. Keller et al.
was performed under a research protocol approved by the 
American Red Cross institutional review board.
Materials and Methods
Mononuclear cells from EDTA peripheral blood were 
used as a source of genomic DNA (QIAamp DSP; QIAGEN, 
Valencia, CA). Genomic DNA was polymerase chain reaction 
(PCR)-amplified and analyzed using two research-use-
only genotyping methods: TaqMan-based sequence-specific 
primer (SSP)-PCR and PCR-restriction fragment length 
polymorphism (RFLP). SSP-PCR using RBC-FluoGene 
ABO Basic test kit was performed as per manufacturer’s 
instructions (inno-train Diagnostik, Kronberg, Germany). 
The RBC-FluoGene ABO Basic test kit interrogates ABO 
c.261G/delG, c.802G/A, c.803G/C, and c.1061C/delC markers. 
Endpoint fluorescence detection was accomplished using the 
FluoVista analyzer and FluoGene software (v.1.5.4.0) (inno-
train Diagnostik), which uses the pattern of detection of 
single nucleotide variants (SNVs) associated with ABO*O.01, 
ABO*O.02, ABO*B, and ABO*A2. The test does not assign 
ABO*A1. When SNVs associated with A2, O1, O2, and B alleles 
are not detected, the software predicts presence of an A allele 
with the stated limitation that the most likely result is A1 but 
that rare alleles cannot be ruled out.
PCR-RFLP interrogating of nucleotides c.261G/delG, 
c.467C/T, c.703G/A, and c.1096G/A, designed to discriminate 
between the common alleles A1, A2, B, O1, and O2, was 
performed as described by Olsson and Chester.5 In a subset 
of cases, Sanger sequencing of ABO exons 1–7 was performed 
(Grifols Immunohematology Center, Grifols Diagnostic 
Solutions, San Marcos, TX). In one case, PCR products of ABO 
gene fragments were cloned into plasmid vectors and subjected 
to Sanger sequencing to determine the phase when multiple 
SNVs were detected and to facilitate allele assignments. 
Sanger sequencing was performed on one sample by the RBC-
FluoGene kit manufacturer (inno-train Diagnostik) using Big 
Dye Terminators 3.1 and the ABI3130 Sequencer.
Results
TaqMan-based SSP-PCR and PCR-RFLP were performed 
for each sample and genotype-predicted phenotypes were 
compared in the context of the serologic information provided. 
The results are summarized and described in Table 1 for 
the patient and donor cohorts. Because FluoGene and RFLP 
methods are both low resolution, there are several limitations 
to each, including inability to rule out subgroups. The presence 
of a subgroup could cause a different genotype result. One 
difference between the two methods is that TaqMan-based 
SSP-PCR calls all non-A2, non-B, non-O1, and non-O2 alleles 
as group A whereas the RFLP interrogates the SNV at c.467, 
which can aid in discriminating between groups A2 and A1. 
Both PCR methods can potentially fail to generate a genotype 
assignment when an unexpected pattern of amplification is 
observed. The samples that were discordant or gave unusual 
banding patterns on RFLP were resolved by high-resolution 
ABO sequencing to determine a definitive genotype (Table 2).
Of the 56 samples genotyped by PCR-RFLP and TaqMan-
based SSP-PCR, 49 (87.5%) gave concordant results. The PCR-
RFLP yielded an unusual banding pattern in three (5.4%) of the 
samples (cases 1–3); this result is often associated with ABO 
variant alleles, which were found in all three samples by high-
resolution testing with the predicted phenotype changing in 
only one of these samples (case 1). In this sample, the SSP-PCR 
ABO*A result is due to a positive non-O1 reaction but cannot 
be explained by the variant allele detected by sequencing. This 
sample was further characterized by Sanger sequencing which 
confirmed the sequencing results of ABO*O1, but no additional 
variants were identified that might explain the SSP-PCR result. 
Considering this unusual and unexpected finding, one could 
speculate that either ABO chimerism or a novel hybrid allele is 
present in this patient.
Four samples (7%) (cases 4–7) gave discordant results 
when comparing FluoGene with RFLP; all involved A versus 
A2 alleles. One donor sample (case 7) was predicted to be group 








N N N N (%)
A/A 1 1 0 1 (100)
A/B 2 2 0 2 (100)
A/O1 28 15 13 22 of 28 (78.5)
A/O2 1 1 0 1 (100)
A2/B 6 4 2 6 (100)
A2/O1 7 5 2 6 of 7 (86)
B/B 1 0 1 1 (100)
B/O1 6 2 4 6 (100)
B/O2 1 1 0 1 (100)
O1/O2 3 0 3 3 (100)
SSP = sequence-specific primer; PCR = polymerase chain reaction;  
RFLP = restriction fragment length polymorphism.
IMMUNOHEMATOLOGY, Volume 35, Number 4, 2019 151
Comparison of ABO genotyping methods
A2 by FluoGene and A1 by RFLP; variant testing identified a 
rare ABO*AW.02 allele that likely caused the discordant result. 
The other three samples (one patient, two donors) carried an 
A2 allele by PCR-RFLP and an A allele by SSP-PCR. Again, 
high-resolution testing identified variants that likely resulted 
in the discordance between the two methods. This finding 
demonstrates that the presence of c.1061delC may be a more 
reliable marker to detect an A2 allele and c.467C>T is prone 
to a false-positive A2 call in a variant allele containing this 
SNV. Both methods have limitations with regard to a correct 
genotype call in the presence of an ABO variant allele.
Four additional patient samples (not listed in Table 2) had 
high-resolution testing as per customer request because of a 
suspected subgroup from serologic typing; three of them were 
found to contain variant alleles. All samples were concordant 
between FluoGene and RFLP. One sample was found to carry 
variant O alleles, changing the predicted phenotype of group A 
from the initial low-resolution methods.
Discussion
We report the concordance of two low-resolution methods 
for ABO genotyping, comparing the predicted phenotype 
from an established PCR-RFLP method with that from a 
commercial TaqMan-based SSP-PCR kit when used for testing 
genomic DNA samples from 56 patients and blood donors. The 
RBC-FluoGene ABO Basic kit uses SSP-PCR with fluorescence 
readout to differentiate between the five target common alleles, 
A, A2, B, O1, and/or O2. It takes 90 minutes to complete, and 
genotype results are generated by the accompanying software. 
The PCR-RFLP method, though involving more hands-on 
time than the commercial TaqMan-based SSP-PCR test, is 
lower cost and involves the use of supplies typically found 
in a molecular laboratory. The main difference between the 
two assays is that the SSP-PCR assay defaults to assigning 
an ABO*A allele when positive amplification of all reactions 
associated with wild-type alleles (“non” reactions) is observed 
in conjunction with a lack of amplification of allele-specific 
(A2, B, O1, or O2) “positive” reactions, whereas the PCR-
RFLP assigns ABO*A1 when the sample is positive for three 
particular SNVs (467C, 703G and 1096G; Table 3). Although 
the differentiation between A and A2 for purposes of blood 
transfusion may be minimal, differentiating A1 from A2 for 
purposes of solid organ transplant is more significant.6
Sanger sequencing blood group antigen genes is considered 
the gold standard when resolving serologic typing or serologic-
genotype discrepancies. Unlike TaqMan-based SSP-PCR and 
PCR-RFLP, Sanger sequencing of the exons and exon-intron 
borders of the ABO gene can detect genetic variation when 
compared with the reference sequence, and therefore is more 
sensitive at detecting alleles encoding subgroups. In this 
sample set, sequencing was used to identify the presence of rare 
group O or A subgroups. Of note, all 16 samples in this study 
that carried a group B allele gave concordant results between 
the two test methods and did not necessitate further sequence 
analysis. Sequencing and sequence alignments can be labor-
intensive and if multiple SNVs are found, allele assignments 
can be equivocal. In this study, 7 of the 56 samples tested using 







1 A/O1 P28 Not provided UBP ABO*O.01.01/ABO*O.01.09 None
2 A/O1 P31 African American UBP ABO*A1.02/ABO*O.01.09 None
3 A/O1 P32 White UBP ABO*A1.01/ABO*O.01.26 Rouleaux demonstrating. Saline replacement 
removes reverse type reactivity.
4 A/O1 P30 African American A2/O1 ABO*O.01/
ABO*IVS1+5861G,467T
Front type: group O 
Back type: group A
5 A/O1 D23 Hispanic A2/O1 ABO*O.01.09/
ABO*IVS1+5860G
Back type: A1 and A2 RBCs (0–w+)
6 A/O1 D25 African American A2/O1 ABO*O.01/
ABO*IVS1+5861G,467T
Front type: group O, anti-A,B reactive
Back type: group A
7 A2/O1 D24 White A1/O1 ABO*AW.02/ABO*O.01.01 Front type: group O, anti-A,B reactive
Back type: group O with weakly reactive A2 RBCs (1+).
Note: O RBCs reactive at room temperature incubation
SSP = sequence-specific primer; PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism; P = patient; UBP= unusual banding 
pattern; D = donor; RBCs = red blood cells.
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the low-resolution methods TaqMan-based SSP-PCR and 
PCR-RFLP yielded discordant results and Sanger sequencing 
was used to determine the alleles and predict the phenotype 
(Table 2).
Of the 56 samples tested, three yielded an atypical 
banding pattern by agarose gel electrophoresis of the PCR-
RFLP reaction. These three samples were predicted to be A/O1 
by TaqMan-based SSP-PCR (Table 2). Sanger sequencing 
yielded allele assignments of two of the three consistent with 
this prediction (cases 2 and 3). All three samples were found 
to carry rare O variant alleles, which explains the uncommon 
banding pattern on the PCR-RFLP. In case 1, however, no 
explanation was found to cause a non-O1 reaction to amplify 
in the TaqMan-based SSP-PCR and result in an ABO*A 
prediction. The ABO*O1.01.09 allele carries the c.261delG, 
resulting in a frameshift and a nonfunctional enzyme. Based 
on this allele assignment, the predicted phenotype for this 
patient is group O. An uncommon banding pattern result from 
PCR-RFLP can provide valuable information to prevent an 
inaccurate group A predicted phenotype and also to propose 
the presence of a variant allele necessitating sequence analysis.
Of the 56 samples tested, three (cases 4–6) were predicted 
to be A/O1 by SSP-PCR and A2/O1 by PCR-RFLP. Sequencing 
analysis resolved the discrepancy by identifying rare alleles 
containing the c.467T variant: two ABO*IVS alleles and one 
group O subgroup. A limitation of the PCR-RFLP is its use of 
the c.467 SNV to differentiate between A1 and A2. Ethnicity 
could be considered to prompt additional testing when an A2 
genotype is assigned from the PCR-RFLP. For example, the 
c.467 SNV is commonly associated with the ABO*A1.02 in 
individuals of Asian descent.7
It is important to note that there is no licensed molecular 
test for predicting the ABO group. Therefore, though 
genotyping can be a useful tool in discrepancy investigations, 
the results cannot be used to label a blood product. Further, 
serologic methods such as use of lectins can be used to resolve 
some discrepancies.3,4
Conclusions
Because of the complexity of the ABO blood group system 
and the limitations of these two platforms, experienced 
molecular immunohematologists are a useful resource when 
interpreting ABO genotyping results. The use of SNV geno-
typing to predict an ABO phenotype requires consideration 
of the platform used, an understanding as to which SNVs are 
detected, and the algorithm used to assign alleles. In addition, 
low-resolution SNV genotyping that leads to an A1 result or a 
result that is not consistent with the serologic results should 
be considered with caution because rare ABO variants cannot 
be excluded. 
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